Invitae Corporation (NYSE:NVTA) Q3 2019 Earnings Conference Call - Final Transcript

Nov 06, 2019 • 04:30 pm ET


Invitae Corporation (NYSE:NVTA) Q3 2019 Earnings Conference Call - Final Transcript


Loading Event

Loading Transcript


Ladies and gentlemen thank you for standing by and welcome to InVitae's Third Quarter 2019 Financial Results Conference Call. At this time all participants are in a listen-only mode. After the speakers' presentation there will be a question-and-answer session. [Operator Instructions]. I would now like to hand the conference over to your speaker today Laura D'Angelo with InVitae. Thank you. Please go ahead.

Laura D'Angelo

Thank you operator and good afternoon everyone thank you for joining us for our third quarter 2019 financial results earnings call. Joining us today are Sean George our CEO; Shelly Guyer our CFO; Bob Nussbaum our CMO Lee Bendekgey our COO; and Katherine Stueland our Chief Commercial Officer. As you listen to today's conference call we encourage you to have our press release available which includes our financial results as well as metrics and commentary on the quarter.

Before we begin I would like to remind you that various remarks that we make on this call that are not historical including those about our future financial and operating results our plans and prospects the focus of our business strategies our plans to integrate and manage businesses we acquire market opportunities future products services our product pipeline and the timing thereof demand for and reimbursement of our services and our investment in our infrastructure and operations constitute forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act.

It is difficult to accurately predict demand for our services and therefore our actual results could differ materially from our guidance. Our guidance on future company performance assumes among other things that we do not include any additional business acquisitions investments restructurings or legal settlements. We refer you to our 10-Q for the quarter ended June 30 2019 in particular to the section titled Risk Factors for additional information on factors that could cause actual results to differ materially from our current expectations.

These forward-looking statements speak only as of the date hereof. To supplement our consolidated financial statements prepared in accordance with Generally Accepted Accounting Principles in the United States or GAAP we provide non-GAAP research and development expense non-GAAP general and administrative expense non-GAAP operating expense non-GAAP net loss and net loss per share and cash burn. We encourage you to review these reconciliations which are available in the press release. With that I will turn the call over to Sean.

Sean George

Thank you Laura. Ten years ago we started InVitae to get genetic information incorporated into mainstream medical use for everyone around the world in modernized economies. While we have many years to go the transformation of the generics industry is underway and we believe our 26th quarter of on average double-digit quarter-over-quarter growth serves as an indication of a new trajectory a new model for personalized medicine as we move this industry beyond the more than 1.7 million people in the US diagnosed with cancer per year into all of the equally impactful genetic disorders affecting those we serve.

As we drive